Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Distress in Crisis Situations During COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04337047
Recruitment Status : Completed
First Posted : April 7, 2020
Last Update Posted : May 5, 2020
Sponsor:
Information provided by (Responsible Party):
benjamin CHAIX, Wefight

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

There are many scales for screening or assessing the impact of a disease. These scales are generally used to diagnose or assess the severity of a disease and are carried out at the request of a physician by the patient. Conversational agents could make it possible to administer these questionnaires remotely, analyse them and use the results on a large scale, without prior medical intervention.

The main objective of this study is to quantify and qualify the distress of a large population in times of pandemic crisis.


Condition or disease Intervention/treatment
Stress, Psychological Other: questionnaire assesment

Detailed Description:

The Peritraumatic Distress Inventory is the standard tool designed to assess distress in times of crisis. It consists of 13 questions.

Questions will be submitted to the participants from the Vik chatbot. Responses will be analysed and compared according to the demographics and pathologies encountered.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Distress During the COVID-19 Pandemic in France: a National Assessment of At-risk Populations
Actual Study Start Date : March 31, 2020
Actual Primary Completion Date : April 30, 2020
Actual Study Completion Date : May 3, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Stress

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Vik sein
Vik sein users
 Other: questionnaire assesment
questionnaire assesment
Vik asthme
Vik asthme users
 Other: questionnaire assesment
questionnaire assesment
Vik migraine
Vik migraine users
 Other: questionnaire assesment
questionnaire assesment
Vik depression
Vik depression users
 Other: questionnaire assesment
questionnaire assesment


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. quantify and qualify distress over a large population in times of pandemic crisis. [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. qualify demographic data vs distress over a large population in times of pandemic crisis. [ Time Frame: 1 month ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Vik's users in France
Criteria

Inclusion Criteria:

  • Age > 18 years old

    • Collection of the subject's non-opposition
    • Patient registration on Vik breast, Vik asthma, Vik migraine, Vik depression

Exclusion Criteria:

  • Patient unable to formulate non-opposition
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04337047


Locations
Layout table for location information
France
Wefight
Montpellier, France, 34000
Sponsors and Collaborators
Wefight
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: benjamin CHAIX, Chief Science Officer, Wefight
ClinicalTrials.gov Identifier: NCT04337047    
Other Study ID Numbers: WefightDistress20
First Posted: April 7, 2020    Key Record Dates
Last Update Posted: May 5, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Stress, Psychological
Behavioral Symptoms